COVID-19 and Diabetes Mellitus: Are there any Differences in Outcomes with Anti-Diabetic Drugs?

Ramazan ÇAKMAK¹, Özge TELCI ÇAKLILI², Ayşe OK², Ümmü MUTLU², Göktuğ SARIBEYLİLER², Vefa SEFEROVA NASIFOVA², Alpay MEDETALİBEYOĞLU⁴, Naci ŞENKAL³, Yunus ÇATMA³, Murat KÖSE³

¹Basaksehir Çam and Sakura City Hospital, Department of Endocrinology and Metabolic Diseases, Istanbul, Turkey
²Istanbul University Faculty of Medicine, Department of Endocrinology and Metabolic Diseases, Istanbul, Turkey
³Istanbul University Faculty of Medicine, Department of Internal Medicine, Istanbul, Turkey

ABSTRACT

Aim: This study aims to analyze the effect of diabetes and diabetes drugs on the outcome of COVID-19 patients.

Material and Methods: All the patients with diabetes hospitalized for COVID-19 between March 15, 2020 and June 15, 2020 at Istanbul University Faculty of Medicine were screened. Outcomes of the patients were compared with patients without diabetes.

Results: Among six hundred fourteen patients (59.8% male, n=367) there were 151 patients with diabetes (24.5%). Patients with diabetes were hospitalized longer than patients without (12.1±10.3 vs. 10.2±7.3, p=0.037 in days), had higher intensive care unit (ICU) hospitalization rate (20.5% (n=31) vs. 12.0% (n=56), p=0.016, OR:1.8 (1.1-2.9)) and mortality rate (15.8% (n=24) vs. 7.7% (n=36, p=0.007), OR:2.1(1.2-3.8)).

There was no difference in admission to ICU between patients who use metformin, basal insulin or bolus insulin regarding admission to ICU compared to patients who don’t (p= 0.32, p=0.22 and p=0.64, respectively). No patient on sodium-glucose co-transporter-2 treatment was treated in ICU. Death rate didn’t differ between patients regarding their treatment modalities.

Conclusion: Patients with diabetes had worse outcomes than non-diabetic patients, and according to our findings and no anti-diabetic drug has a beneficial or harmful effect.

Keywords: COVID-19, Diabetes medication, Sodium-glucose co-transporter-2, Metformin

Cite this article as: Çakmak R et al. COVID-19 and diabetes mellitus: Are there any differences in outcomes with anti-diabetic drugs? Turk J Diab Obes 2021;3: 279-284.
INTRODUCTION

Novel coronavirus disease 2019 (COVID-19) has caused a global pandemic and affected millions of people worldwide (1). Patients with advanced age, co-morbidities and immunosuppression are reported to be at greater risk of morbidity and mortality (2,3). Whether diabetes poses a higher risk for disease progression, hospitalization and death is still at question.

Various reports have shown an increased risk of death from diabetes for COVID-19 patients. Guan et al. reported that there were more patients with diabetes in their cohorts who experienced serious illness than the normal population (4). Guo et al. has shown increased inflammatory response in patients with COVID-19 and diabetes compared to patients without (5). Guo et al. has reported increased mortality among patients with diabetes compared to patients with other co-morbidities (6).

As the first line pharmacologic treatment of diabetes, metformin is under investigation for its effects on COVID-19 patients (7,8). Insulin and other drug classes are tested for their impact on the outcome of COVID-19 patients. This study aims to analyze the effect of diabetes and diabetes drugs on outcome of COVID-19 patients.

MATERIALS and METHODS

Ethics

Approval for the study was obtained from both Turkish Ministry of Health (2020-05-14T12_59_48) and blinded for peer review Faculty of Medicine Ethics Committee (rule number: 08/06/2020-91658). Rules of Helsinki Declaration were followed through the study.

Subjects

All the patients hospitalized for COVID-19 between March 15, 2020 and June 15, 2020 at blinded for peer review Faculty of Medicine were screened. Patients demographic characteristics were recorded from their medical records and patient history in their files. Patients were excluded if they were younger than 18 years.

Patient files were screened for (1) diabetes drugs patients used until the hospitalization (drug changes necessary during the hospitalization were not included to the analysis), (2) hospitalization outcomes (discharge, intensive care unit (ICU), death etc.). Outcomes were compared with patients without diabetes (control group). Patients' admission laboratory data were compared regarding their diabetes status.

Statistical Analysis

Statistical analysis was performed using the SPSS software version 16. Normality of the variables were tested using visual (histogram) and analytic methods (Kolmogorov-Smirnov/Shapiro-Wilk's test). Kruskal-Wallis and Mann-Whitney U tests were conducted to compare parameters among groups. Pearson and Spearman correlation methods were used to test correlations. Chi square test was used to determine an association between two categorical values. And correlation of a nominal and a categorical data were analyzed with the Eta value. An overall 5% type-I error level was used to infer statistical significance.

RESULTS

Six hundred fourteen patients (59.8% male, n=367) were included. There were 151 patients with diabetes (24.5%). Patients with diabetes were significantly older than patients without (63.2±12.5 vs. 55.4±15.9, p<0.001 in years) (Table 1). At admission patients with diabetes had lower oxygen saturation level (93.0±5.7 vs. 94.6±4.2, p=0.002 in %), similar body temperature (37.1±1.3 vs. 37.3±0.9, p=0.095 in Celsius degree), higher systolic blood pressure (135±20.0 vs. 129±21.3, p=0.003 in mmHg) and higher respiratory rate (20.8±5.1 vs. 19.5±4.6, p=0.008 per minute) compared to controls (Table 1).

When patient outcomes were analyzed; patients with diabetes were hospitalized longer than patients without (12.1±10.3 vs. 10.2±7.3, p=0.037 in days), however there was no statistically significant difference between hospitalization days in ICU (26.5±20.4 vs. 24.6±19.0, p=0.688). No difference was observed between groups regarding days from hospitalization to ICU (1.5±4.75 (IQR) vs. 2±6 (IQR), p=0.159). Patients with diabetes had higher ICU hospitalization rate (20.5 % (n=31) vs. 12.0% (n=56), p=0.016, OR:1.8 (1.1-2.9)) and mortality rate (15.8% (n=24) vs. 7.7% (n=36, p=0.007), OR:2.1 (1.2-3.8)).

Among patients with diabetes 103 patients (68%) had hypertension. Mean glucose level was 181.9±73 mg/dL. Mean HbA1c percent was 7.2±1.8. Patients had a mean duration of diabetes as 8.9±7.1 years. There were 29 patients (19%) with coronary heart disease and 21 patients (14%) with heart failure. ICU admission rate and death rate were 20.5 % (n=31) and 15.9% (n=24), respectively. A hundred and five patients (69.5 %) were on metformin treatment, 35 patients (23.1 %) on basal insulin and 21 (13.9%) patients on basal and bolus insulin treatment (Table 2). Only 8 patients were on pre-mixed insulin treatments. There were 37 patients (24.5%) on statin treatment. No difference was observed in terms of outcomes between statin users and non-users.
There was no difference in admission to ICU between patients who use metformin and patients who don’t (p=0.32), (Table 3). No difference was observed between patients who use basal insulin or bolus insulin regarding admission to ICU compared to patients who don’t use these agents (p=0.22 and p=0.64, respectively). No patient on SGLT-2 inhibitor treatment (12 patients were on SGLT-2 inhibitor treatment) was treated in ICU. Death rate didn’t differ between patients who use metformin, basal insulin, bolus insulin, pioglitazone, sulfonylureas, DPP-4 inhibitors and SGLT-2 inhibitors (Table 3).

Table 1: Comparison of preadmission laboratory parameters of patients with and without diabetes.

| Parameters                        | DM (n=151)       | Non-DM (n=463)  | P value |
|-----------------------------------|------------------|----------------|---------|
| Age, years                        | 63.2±12.5        | 55.4±15.9      | <0.001  |
| Duration of hospitalization, days | 12.1±10.3        | 10.2±7.3       | 0.03    |
| Duration of ICU, days             | 26.5±20.4        | 24.6±19.0      | 0.68    |
| Height, cm                        | 166.0±8.1        | 167.9±9.7      | 0.40    |
| Body weight, kg                   | 82.5±14.1        | 82.1±14.8      | 0.98    |
| Body mass index, kg/m²            | 30.5±5.8         | 28.8±4.4       | <0.01   |
| Body temperature, °C              | 37.1±1.3         | 37.3±0.9       | 0.60    |
| SpO2, %                           | 93.00±5.7        | 94.64±4.2      | <0.001  |
| Systolic blood pressure, mmHg     | 135.20±20.1      | 129.20±21.3    | <0.01   |
| Diastolic blood pressure, mmHg    | 78.4±12.4        | 77.3±11.8      | 0.28    |
| Pulse rate                        | 95.20±16.9       | 95.18±13.4     | 0.05    |
| Respiratory rate                  | 20.8±5.1         | 19.5±4.6       | 0.03    |
| pH                                | 7.40±0.08        | 7.40±0.07      | 0.35    |
| pO2, mmHg                         | 66.78±16.1       | 62.71±15.3     | 0.38    |
| pCO2, mmHg                        | 38.67±8.7        | 40.61±8.6      | 0.81    |
| HCO3, mEq/L                       | 23.11±3.7        | 24.19±3.2      | 0.14    |
| Lactate, mEq/L                    | 2.22±2.2         | 1.77±1.1       | <0.001  |
| Hemoglobin, gr/L                  | 12.24±2.1        | 12.94±2.0      | 0.89    |
| Platelet, 10^6/L                  | 240942±102395    | 227813±93060   | 0.07    |
| Leukocyte, 10^6/L                 | 8535±9587        | 7108±3480      | <0.001  |
| Creatinine, mg/dL                 | 1.02±0.4         | 1.11±1.2       | 0.09    |
| Sodium, mEq/L                     | 136.74±4.3       | 137.93±4.9     | 0.67    |
| Potassium, mEq/L                  | 4.39±0.5         | 4.50±5.0       | 0.57    |
| Fasting plasma glucose, mg/dL     | 172.9±72.8       | 118.7±42.8     | <0.001  |
| Aspartate aminotransferase, IU/L   | 34.49±34.2       | 36.22±32.1     | 0.92    |
| Alanine aminotransferase, IU/L     | 30.64±46.1       | 33.10±46.5     | 0.70    |
| Lactate dehydrogenase, U/L        | 281.42±111.9     | 279.84±135.2   | 0.60    |
| Albumin, g/dL                     | 3.83±0.5         | 3.92±0.5       | 0.37    |
| Triglyceride, mg/dL               | 123.71±72.8      | 121.42±71.2    | 0.63    |
| Procalcitonin, ng/mL              | 0.46±1.5         | 0.62±3.9       | 0.31    |
| Ferritin, mg/L                    | 475.49±654.4     | 805.20±4016.8  | 0.22    |
| D-dimer, ng/mL                    | 1715±2694        | 1492±2289      | 0.42    |
| Troponin, ng/mL                   | 41.85±125.2      | 33.75±185.9    | 0.67    |
| CRP, mg/L                         | 74.31±66.9       | 70.83±78.5     | 0.44    |

CRP: C-reactive protein, DM: Diabetes mellitus.
DISCUSSION

This study reports that death and ICU admission rate of patients with diabetes were significantly higher than patients without diabetes in a university hospital.

Outcomes of COVID-19 patients with diabetes differ significantly according to region, country, ethnicity and available treatments. A cohort from a New York Hospital reports (9) death rate as 10.2%, whereas another report from USA with a cohort from different states (10) has higher death rate as 28%. In a report from Italy this rate is as high as 48% (11). Their cohort was relatively older than our patients. Our death rate is 15.8% among patients with diabetes and it’s almost twice the rate of patients without diabetes. A meta-analysis with 83 studies has revealed two-fold increase in severe/clinical illness (12) compatible with our results and our OR.

Also, because our cohort is from a tertiary university hospital where our control patients (patients without diabetes) had other morbid disorders such malignancies, chronic kidney disease etc., these results can be interpreted as an understatement of the real risk. Holman et al. showed increased mortality rate with HbA1c levels > 7.6% compared to levels lesser (13). In our study mean HbA1c was 7.2%. This could have also affected our results.

Patients on metformin did not have different mortality or morbidity rate compared to patients without this treatment. Role of metformin on COVID-19 related morbidities is not clear yet. There are reports of improved outcomes with metformin as well as without significant difference (14). SGLT-2 inhibitors are also among drugs which are under attention. Dalan et al. reported lower risk of mechanical ventilation with SGLT-2 inhibitors (15). Whether this beneficial effect is the result of cardiovascular protection obtained with these agents or an unknown pleiotropic effect, is the question of a larger randomized trial. There is an ongoing clinical trial to investigate the effects of dapagliflozin in COVID-19 which can hopefully address these inquiries and calculate euglycemic ketoacidosis risk with these agents can bring to COVID-19 infection. In our study patients on SGLT-inhibitors had relatively lower rate of ICU admission and mortality, however this difference didn’t reach statistical significance due to small sample size.

In our cohort insulin use was not associated with better or worse outcomes. Yu et al. has reported that insulin use was associated with enhanced inflammation (16). Riahi et al. has reported that insulin therapy increased mortality risk in both inpatients and outpatients (17). These findings are not unexpected due to the conditions in which insulin is used. Patients on insulin are often patients with poor glycemic control and/or patients with advanced age and diabetes duration in need for insulin therapy.

DPP-4 inhibitors had no effect on mortality or ICU admission. Our cohort had relatively small number of

| Table 2: Frequency of anti-diabetic drug classes. |
|-----------------------------------------------|
| **Anti-Diabetic Drugs** | **Case proportions (Total n=151)** |
| **n** | **%** |
| Metformin | 105 | 69.5 |
| Basal insulin | 35 | 23.1 |
| Bolus insulin | 21 | 13.9 |
| Pre-mixed insulin | 8 | 5.0 |
| Pioglitazone | 10 | 6.6 |
| DPP-4 inhibitors | 29 | 19.2 |
| Sulfonylureas | 32 | 21.1 |
| SGLT-2 inhibitors | 12 | 7.9 |

DPP-4: Dipeptidyl peptidase-4, SGLT-2: Sodium Glucose Co-transporter.

| Table 3: Outcomes with different anti-diabetic drug classes. |
|-----------------------------------------------|
| **Outcomes** | **ICU Admission Rate** | **Mortality Rate** |
| | **Treated with** | **Treated without** | **P** | **Treated with** | **Treated without** | **P** |
| | **n** | **%** | **n** | **%** | **n** | **%** | **n** | **%** |
| Metformin | 18 | 62 | 11 | 38 | 0.321 | 15 | 62.5 | 9 | 37.5 | 0.414 |
| Basal insulin | 4 | 13.7 | 25 | 86.3 | 0.183 | 4 | 16.6 | 20 | 83.4 | 0.410 |
| Bolus insulin | 4 | 13.7 | 25 | 86.3 | 0.984 | 4 | 16.6 | 20 | 83.4 | 0.670 |
| Pioglitazone | 3 | 10.3 | 26 | 89.7 | 0.595 | 4 | 16.6 | 20 | 83.4 | 0.085 |
| DPP-4 inhibitors | 6 | 20.6 | 23 | 79.4 | 0.72 | 3 | 12.5 | 21 | 87.5 | 0.176 |
| Sulfonylurea | 2 | 6.9 | 27 | 93.1 | 0.12 | 4 | 16.6 | 20 | 83.4 | 0.823 |
| SGLT-2 inhibitors | 0 | 0 | 29 | 100 | 0.11 | 2 | 8.3 | 22 | 91.7 | 0.98 |

ICU: Intensive care unit, DPP-4: Dipeptidyl peptidase-4, SGLT-2: Sodium glucose co-transporter.
patients on DPP-4 inhibitors (n=29, 19%) which may have lowered its impact on analysis. Solerte et al. has suggested that gliptins may reduce virus entry and replication in a molecular level (18). From real life data, Strollo et al. has reported no difference with DPP-4 inhibitors in prevention or progression of COVID-19 (19).

Limitations of our trial include observational nature of the study. Also, our results are from a tertiary unit, therefore our results may not be reflecting general population. Our analysis includes drugs used in preadmission, thus any changes of diabetes drugs during COVID-19 therapy is not reflected in our report.

As a result, diabetic patients had worse outcomes than non-diabetic patients, and according to our findings and no anti-diabetic drug has a beneficial or harmful effect.

Acknowledgments
None.

Author Contributions
Concept: Ramazan Çakmak, Design: Ramazan Çakmak,
Data Collection or Processing: Vefa Seferova Nasifova, Alpay Medetalibeyoğlu, Yunus Çağtha, Naci Şenköl, Murat Kösse,
Analysis or Interpretation: Özge Telci Çakılı, Ramazan Çakmak,
Literature Search: Ümmü Mutlu, Aysçe Merve Ok, Gökşü Sarbayanlı,
Writing: Ramazan Çakmak, Özge Telci Çakılı.

Conflict of Interest
The authors declare that they have no competing interest.

Financial Support
The authors received no financial support for this study.

Ethical Approve
The Ministry of Health approval for the study was received on 19.05.2020 with the approval number 2020-05-14T12_59_48. Approval was obtained from the Ethics Committee of Istanbul Faculty of Medicine on 21.05.2020.

Peer-Review Process
Extremely peer-reviewed and accepted.

REFERENCES
1. Ji Y, Ma Z, Peppelenbosch MP, Pan Q. Potential association between COVID-19 mortality and health-care resource availability. Lancet Glob Health. 2020;8(4):e480.

2. Imam Z, Odish F, Gill I, O’Connor D, Armstrong J, Vanood A, Ibronke O, Hanna A, Ranski A, Halalau A. Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States. J Intern Med. 2020;288(4):469-476.

3. Poblador-Plou B, Carmona-Pirez J, Ioakeim-Skoufia I, Poncel-Falcó A, Blied-Bueno K, Cano-De Pozo M, Gimeno-Feliú LA, Gónzalez-Rubio F, Aza-Pascual-Salcedo M, Bandrés-Liso AC, Díez-Manglano J, Marta-Moreno J, Mucherino S, Gimeno-Miguel A, Prados-Torres A, EpiChron Group. Baseline Chronic Comorbidity and Mortality in Laboratory-Confirmed COVID-19 Cases: Results from the PRECOVID Study in Spain. Int J Environ Res Public Health. 2020;17(14):5171.

4. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhong Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395(10229):1045-1062.

5. Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, Qin R, Wang H, Shen Y, Du K, Zhao L, Fan H, Luo S, Hu D. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Rev. 2020:e3319.

6. Guo L, Shi Z, Zhang Y, Wang C, Do Valle Moreira NC, Zuo H, Akhtar H. Comorbid diabetes and the risk of disease severity or death among 8807 COVID-19 patients in China: A meta-analysis. Diabetes Res Clin Pract. 2020;166:108346.

7. Cheng X, Liu YM, Li H, Zhang X, Lei F, Qin j, Chen Z, Deng K, Lin L, Chen M, Song X, Xia M, Huang X, Liu W, Yuan Y, Wei X, She ZG, Ji YX, Li H. Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes. Cell Metab. 2020;32(4):537-547.e3.

8. Sharma S, Ray A, Sadasivam B. Metformin in COVID-19: A possible role beyond diabetes. Diabetes Res Clin Pract. 2020;164:108183.

9. Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Assem JS, Satlin MJ, Campion TR, Nahid M, Ringel JB, Hoffman KL, Alshak MN, Li HA, Wehmeyer GT, Rajan MR, Evgeniya HN, Horn EM, Martinez FJ, Gulick RM, Safford MM. Clinical Characteristics of Covid-19 in New York City. N Engl J Med. 2020;382(24):2372-2374.

10. Bode B, Garrett V, Messler J, McFarland R, Crowe J, Booth r, Klonof DC. Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States. J Diabetes Sci Technol. 2020;14(4):813-821.

11. Ciardullo S, Zerbini F, Perra S, Muraca E, Cannistraci R, Lauriola M, Grosso P, Lattuada G, Ippoliti G, Mortara A, Manzoni G, Perseghin G. Impact of diabetes on COVID-19-related in-hospital mortality: A retrospective study from Northern Italy. J Endocrinol Invest. 2021;44(10):823-834.

12. Mantovani A, Byrne CD, Zheng MH, Tagher G. Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: A meta-analysis of observational studies. Nutr Metab Cardiovasc Dis. 2020;30(8):1236-1248.

13. Holman N, Knighton P, Kar P, O’Keefe J, Curley M, Weaver A, Barron E, Bahktai C, Khunti K, Wareham NJ, Sattar N, Young B, Valabhi J. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: A population-based cohort study. Lancet Diabetes Endocrinol. 2020;8(10):823-833.
14. Chen Y, Yang D, Cheng B, Chen J, Peng A, Yang C, Liu C, Xiong M, Deng A, Zhang Y, Zheng L, Huang K. Clinical Characteristics and Outcomes of Patients with Diabetes and COVID-19 in Association with Glucose-Lowering Medication. Diabetes Care. 2020;43(7):1399-1407.
15. Dalan R, Ang LW, Tan WYT, Fong S-W, Tay WC, Chan YH, Renia L, Lisa FP, Lye DC, Chew DEK, Young BE. The association of hypertension and diabetes pharmacotherapy with COVID-19 severity and immune signatures: An observational study. Eur Heart J Cardiovasc Pharmacother. 2021;7(3):e48-e51.
16. Yu B, Li C, Sun Y, Wang DW. Insulin Treatment Is Associated with Increased Mortality in Patients with COVID-19 and Type 2 Diabetes. Cell Metab. 2021;33(1):65-77.e2.
17. Riahi S, Sombra LRS, Lo KB, Chacko SR, Neto AGM, Azmaiparashvili Z, Patarroyo AG, Rangaswami J, Anastasopoulou C. Insulin Use, Diabetes Control, and Outcomes in Patients with COVID-19. Endocr Res. 2021;46(2):45-50.
18. Solerte SB, Di Sabatino A, Galli M, Fiorina P. Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19. Acta Diabetol. 2020;57(7):779-783.
19. Strollo R, Maddaloni E, Dauriz M, Pedone C, Buzzetti R, Pozzilli P. Use of DPP4 inhibitors in Italy does not correlate with diabetes prevalence among COVID-19 deaths. Diabetes Res Clin Pract. 2021;171:108444.